AI-generated summary
The authors report a secondary analysis of a randomized trial of photobiomodulation, alone or with oral cryotherapy, in burning mouth syndrome patients followed for 12 months. Among responders, 54.4 percent experienced pain recurrence within 2.55 to 5.33 months, and xerostomia and mental stress were potentially associated with higher recurrence risk. The authors describe these findings as preliminary and requiring confirmation in larger trials.
- Participants
- 93
- Who or what was studied
- Patients with burning mouth syndrome (93 patients, 68 classified as responders) from a randomized clinical trial, assigned to photobiomodulation plus oral cryotherapy, photobiomodulation alone, oral cryotherapy, or drug therapy.
- Limits stated in the abstract
- The authors state the findings are preliminary, come from a secondary analysis, and require confirmation in larger trials.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on linkinghub.elsevier.com.
Record from PubMed, a service of the National Library of Medicine.
How to read a trial: what to check before relying on this kind of research.
Terms in this paper: Photobiomodulation, Randomized controlled trial, Visual analogue scale, Statistical significance, Anxiety. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.